About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Atorvastatin and ezetimibe
- Company
- Dr. Md. Alimur Reza
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 4 recruiting
Efficacy results: Not yet reported
4 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Oct 8, 2026
Find a Clinical Trial Near Me
See recruiting studies for Atorvastatin and ezetimibe and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT04347434
Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
Not yet reported Penza State University 300 participants Est. completion 2027-12-30 1 siteCardiovascular disease Other conditions: Myocardial Strain, Arterial Stiffness, Quality of LifeView official trial listing → -
Recruiting NCT NCT05365438
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Not yet reported Seoul National University Bundang Hospital 105 participants Est. completion 2026-12-31 1 siteType 2 diabetes Other conditions: Dyslipidemias, AtherosclerosisView official trial listing → -
Recruiting NCT NCT06784557
Effect of Ezetimibe on Gut Microbiota
Not yet reported Yonsei University 110 participants Est. completion 2025-10-01 1 siteCardiovascular diseaseView official trial listing → -
Recruiting NCT NCT07036991
A Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis
Changhai Hospital 406 participants Est. completion 2027-06-01 1 siteOther conditions: Carotid Artery StenosisView official trial listing → -
Status unknown NCT NCT00433823
A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis
Not yet reported Abant Izzet Baysal University Est. completion 2008-01 1 siteOther conditions: Coronary Heart Disease, Diabetes Mellitus, Non-Coronary Atherosclerotic Disease, HypercholesterolemiaView official trial listing → -
Completed NCT NCT00639158
Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood
Not yet reported Abbott 543 participants 118 sitesOther conditions: Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed DyslipidemiaView official trial listing → -
Completed NCT NCT00681525
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
Not yet reported Abbott 18 participants 1 siteOther conditions: PharmacokineticsView official trial listing → -
Completed NCT NCT00871351
Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)
Not yet reported Organon and Co 125 participants Est. completion 2010-05-01 Stand-aloneOther conditions: Primary HypercholesterolemiaView official trial listing → -
Terminated NCT NCT00965055
Ezetimibe in Patients Hypo-responsive to Statins
Not yet reported University of California, San Diego 2 participants Est. completion 2012-09 1 siteCardiovascular disease Other conditions: High CholesterolView official trial listing → -
Status unknown NCT NCT01086020
Atorvastatin Plus Ezetimibe on Coronary Plaque Progression
Not yet reported Shanghai Jiao Tong University School of Medicine 400 participants Est. completion 2012-12 1 siteCardiovascular diseaseView official trial listing → -
Completed NCT NCT01370590
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
Not yet reported Organon and Co 406 participants Est. completion 2012-04Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT01370603
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
Not yet reported Organon and Co 328 participants Est. completion 2012-05Other conditions: HypercholesterolemiaView official trial listing → -
Completed NCT NCT01709513
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
Not yet reported Regeneron Pharmaceuticals 314 participants Est. completion 2017-05-31 70 sitesOther conditions: HypercholesterolemiaView official trial listing → -
Terminated NCT NCT02227784
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
Not yet reported Eli Lilly and Company 366 participants Est. completion 2015-12 64 sitesOther conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT02288338
CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 36 participants Est. completion 2015-02 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT02451098
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
Not yet reported Chong Kun Dang Pharmaceutical 385 participants Est. completion 2016-01 1 siteOther conditions: HyperlipidemiaView official trial listing → -
Completed NCT NCT04061824
Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia
Not yet reported Yonsei University 150 participants Est. completion 2018-12-20 1 siteOther conditions: Hypertension, DyslipidemiasView official trial listing → -
Status unknown NCT NCT04701242
Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"
Not yet reported Cairo University 500 participants Est. completion 2025-12 1 siteCardiovascular disease Other conditions: DyslipidemiasView official trial listing → -
Active, not recruiting NCT NCT04862260
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
Not yet reported CHU de Quebec-Universite Laval 3 participants Est. completion 2026-12-31 2 sitesOther conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer, Metastatic CancerView official trial listing → -
Status unknown NCT NCT04900155
Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19
Not yet reported Penza State University 45 participants Est. completion 2024-12 1 siteOther conditions: STEMI, Covid19, NSTEMIView official trial listing → -
Completed NCT NCT05559606
An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe
Boryung Pharmaceutical Co., Ltd 1839 participants Est. completion 2025-07-30 1 siteOther conditions: Primary HypercholesterolemiaView official trial listing → -
Active, not recruiting NCT NCT05910476
Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial)
Not yet reported Yonsei University 200 participants Est. completion 2026-09-22 1 siteCardiovascular disease Other conditions: DyslipidemiasView official trial listing → -
Withdrawn NCT NCT06789432
Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population
Not yet reported Dr. Md. Alimur Reza Est. completion 2025-12 1 siteOther conditions: Hyperlipidemia (E.G., Hypercholesterolemia)View official trial listing → -
Completed NCT NCT07489183
A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older
Dong Wha Pharmaceutical Co. Ltd. 641 participants Est. completion 2023-09-07 1 siteOther conditions: HypercholesterolemiaView official trial listing → -
Not yet recruiting NCT NCT07508254
Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome
Not yet reported Punjab Institute of Cardology 120 participants Est. completion 2026-10-31 1 site Stand-aloneOther conditions: Acute Coronary Syndromes (ACS), HypercholesterolemiaView official trial listing → -
Not yet recruiting NCT NCT07685054
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
Boryung Pharmaceutical Co., Ltd 12700 participants Est. completion 2029-08-15Other conditions: Essential Hypertension, Primary HypercholesterolemiaView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Atorvastatin and ezetimibe, Atorvastatin 10 mg and ezetimibe 10 mg
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.